A new era for Cabozantinib tablets: from approval for multiple indications to the practical value of combination immunotherapy

CabozantinibTabletsA new era for Cabozantinib: from approval for multiple indications to the practical value of combination immunotherapy

Cabozantinib (Cabozantinib) is a multi-target tyrosine kinase inhibitor (including MET, VEGFR, AXL, etc.). In the past decade, it has evolved from a single-target small molecule to a multi-indication, combined immunotherapy The strategic change in immunotherapy has brought new treatment options for renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC) and neuroendocrine tumors (NET). Clinical evidence of synergistic effects between its pharmacological "broad-spectrum attack" and immune checkpoint inhibitors (ICIs) is prompting global guidelines to reshape medication sequences and combination strategies.

xa0

1. From single target to multiple pathways: a new pattern of cabozantinib’s anti-cancer mechanism

Cabozantinib (Cabozantinib) is a multi-target tyrosine kinase inhibitor that is unique in that it simultaneously inhibits multiple signaling pathways, including MET, VEGFR2, AXL, RET, etc. These pathways play a key role in tumor angiogenesis, cell proliferation, invasion and metastasis. Unlike traditional single-target drugs, cabozantinib cuts off the blood supply and growth signals of tumors through "multi-point blockade", providing a more comprehensive control strategy for advanced solid tumors.

This multiple targeting mechanism allows cabozantinib to not only inhibit tumor growth, but also improve the immune microenvironment and create more favorable conditions for immunotherapy. Therefore, cabozantinib is considered to be one of the important core drugs in the era of "targeted + immune" combination, and has been included in multinational cancer treatment guidelines.

2. The latest global indication progress: from renal cancer to neuroendocrine tumors

Since the advent of cabozantinib, its indications have continued to expand, and it has been approved in many countries for four major cancer types: renal cell carcinoma (RCC), hepatocellular carcinoma (HCC), differentiated thyroid cancer (DTC) and pancreatic neuroendocrine tumors (pNET).

1. Renal cell carcinoma (RCC)

Cabozantinib first showed excellent efficacy in renal cancer. It can effectively block the VEGFR signaling pathway, inhibit the formation of new blood vessels, and thereby "starve" tumor cells. In recent years, the combination regimen of cabozantinib and PD-1 inhibitors has shown obvious advantages in clinical trials, making it one of the first-line recommended regimens for advanced RCC.

2. Hepatocellular carcinoma (HCC)

For HCC patients who have failed sorafenib treatment Cabozantinib can be used as a second-line treatment. Its mechanism of action is not limited to inhibiting angiogenesis, but can also interfere with the tumor microenvironment and prevent cancer cell metastasis. Studies have shown that cabozantinib can improve tumor control rates and prolong survival. It is currently one of the important targeted treatment options in the world.

3. Differentiated thyroid cancer (DTC)

For patients with differentiated thyroid cancer who are refractory to radioactive iodine therapy, cabozantinib has become one of the standard back-line drugs. It can inhibit the RET and VEGFR pathways and effectively delay tumor progression. Clinical data show that patients' disease stabilization time is significantly prolonged after use.

4. Pancreatic neuroendocrine tumors (pNET)

The latest progress shows that cabozantinib has been approved in some countries for the treatment of pancreatic and ectopic neuroendocrine tumors that have previously received other systemic treatments. This marks Cabozantinib's entry into the field of more complex and rare tumors, bringing new hope to patients with advanced NET.

3. Trends in the combination of cabozantinib and immunotherapy

After the rise of immune checkpoint inhibitors (ICI), scientists found that cabozantinib can significantly enhance the immune response. It modulates tumor blood vessels and the immunosuppressive cellular microenvironment, making it easier for the immune system to recognize and attack cancer cells.

In multiple clinical studies, the combination treatment of cabozantinib and immunological drugs such as nivolumab (nivolumab) has shown higher response rates and longer progression-free survival than single drugs. Clinically, this combination regimen has become the mainstream treatment model for advanced tumors such as renal cancer, and is also being extended to liver cancer, thyroid cancer, and neuroendocrine tumors.

4. Resistance and dose management: key challenges in long-term treatment

Although cabozantinib is effective, resistance may develop with long-term use. Studies believe that drug resistance mainly results from the activation of alternative signaling pathways, genetic mutations, or compensatory growth of tumor cells. To delay the emergence of drug resistance, doctors usually use the following strategies:

Conduct regular molecular testing to discover new target mutations;

Combined with immune drugs or other targeted drugs at the appropriate time;

Strictly monitor drug exposure and adverse reactions to avoid reduction in efficacy due to toxicity.

Dosage adjustment is equally important. The recommended starting dose of cabozantinib varies slightly in different countries, generally 40 mg to 60 mg orally once daily. When moderate or severe adverse reactions occur, the dose can be reduced to 20 mg or treatment can be interrupted to ensure long-term benefit for the patient.

5. Adverse reactions and daily management suggestions

The adverse reactions of cabozantinib are mostly controllable, but require professional monitoring. The most common side effects include fatigue, diarrhea, hand-foot syndrome, high blood pressure, and thyroid dysfunction. A small number of patients may experience severe bleeding or intestinal perforation, and the risks should be strictly assessed under the guidance of a doctor. Daily management suggestions are as follows:

Monitor blood pressure and cardiac function: High blood pressure is a common side effect and should be combined with antihypertensive drugs.

Pay attention to liver and kidney indicators: check functional levels regularly before and after treatment.

Skin care: Hand-foot syndrome can be reduced by moisturizing and avoiding friction.

Nutritional support: A reasonable diet can reduce fatigue and loss of appetite.

Through standardized monitoring and early intervention, most patients can safely complete the treatment and maintain a good quality of life.

6. Global market status and price differences

The original drug cabozantinib was developed by an international pharmaceutical company and has not yet been officially launched in mainland China. However, multiple versions are sold in Hong Kong and overseas markets. Common specifications in Hong Kong include20mg, 40mg, and 60mg tablets, with about 30 tablets per box and selling for about 50,000 yuan; while in Japan, Europe, Turkey and other regions, the price is slightly lower, ranging from about 30,000 to 40,000 yuan per box.

It is worth noting that generic drugs are already on the market in some Asian countries and regions. For example, the Laos, Bangladesh, and Indian versions of cabozantinib have basically the same efficacy as the original drug, but the price has dropped significantly. Taking the Lao version as an example, the price of 20mg*90 tablets is less than 1,000 yuan. This has greatly improved access to medicines for patients in some countries.

However, when choosing generic drugs, patients should pay attention to the quality of the drugs and the formality of the channels, and ensure that they purchase pharmaceutical companies or medical institutions with their own production qualifications to avoid affecting the efficacy.

xa0

7. China’s market outlook and policy direction

At present, cabozantinib has not yet obtained marketing authorization in mainland China, which means that patients mainly obtain the drug through overseas purchase, clinical trial participation or specially approved introduction. As China's drug review and approval system accelerates, cabozantinib is expected to be officially introduced into the domestic market in the next few years.

From a policy perspective, the price negotiation mechanism for oncology drugs at home and abroad has gradually matured. Once the original drug is launched, inclusion in the medical insurance catalog will become an important means to promote accessibility. At the same time, the research and development of domestic generic drugs is also accelerating, and in the future it is expected to significantly reduce drug costs while ensuring quality.

8. Enlightenment from the patient’s perspective: scientific decision-making and international medication channels

For Chinese patients, the emergence of cabozantinib represents the trend of a new generation of targeted drugs, and also reflects the individualization and diversification of global anti-cancer strategies.

For patients with advanced tumors who have failed standard treatments, cabozantinib offers a new opportunity to extend survival;

For doctors, it broadens the idea of combining targeting and immunity;

For policymakers, it is important to pay attention to the registration speed of imported innovative drugs and the medical insurance negotiation mechanism.

Currently, some hospitals and cross-border pharmacies are able to assist patients in obtaining overseas drugs through formal channels, but they still need to use them rationally under the guidance of a doctor to avoid changing or discontinuing drugs on their own.

References:

FDA — FDA approves cabozantinib for adults and pediatric patients 12 years of age and older with pNET and epNET.

NEJM — CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib in advanced RCC.

FDA — Cabozantinib approval for hepatocellular carcinoma.

U.S. Food and Drug Administration

FDA — Cabozantinib approval for differentiated thyroid cancer (DTC).

U.S. Food and Drug Administration

CABOMETYX latest prescribing information and labels (AccessData / FDA label PDF).